You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events

    SBC: CAPELLA IMAGING, LLC            Topic: NHLBI

    Despite the myriad major advances in cardiologythe prognosis for patients with severemedically refractive heart failureHFis exceedingly poorApproximatelydeaths occur annually in patients with HF who have endured an impaired quality of life often accompanied by significant economic and personal losses due to recurrent hospitalizationsAt leastof these deaths were directly related to severe heart fai ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygenOcarrier to substitute for banked blood in settings wherestored blood is unavailablepre hospital care transportaustere environmentsundeveloped countriesorundesirabletransfusion risk exceeds benefitTo address this needwe developedErythroMerEMa first inclass nano cyte blood substituteEM is a deformablecross linked polymeric nanoparticle that inco ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. eCPAT: Advancing public park information and technology resources to diverse audiences for healthy communities

    SBC: EnQ LLC            Topic: NCI

    Project Summary Abstract Quality parks provide numerous benefits to individuals and communitiesincluding health cost savings through physical activity and stress reliefincreased tax revenue via augmented property values and attracting businessesand positive social and environmental impacts through outcomes such as civic pride and pollution controlThe Community Park Audit ToolCPATprovides a compreh ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. An unique patient population for clinical trials against noise-induced hearing loss

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    AbstractNoise is the number one occupational and environmental hazardand noiseinduced hearing lossNIHLis one common form of sensorineural hearing deficitonly second to age related hearing lossCurrently no drug preventing NIHL is approved by the United States Food and Drug AdministrationFDAOne major challenge for the introduction of such interventions is the need to identify appropriate human popul ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Improving the Design of CRISPR/Cas9 Knockout Assays

    SBC: Nawgen, LLC            Topic: 400

    Project Summary The CRISPR Cassystem has been developed in recent years for genome editingand it has been rapidly and widely adopted by the scientific communityThe main objective of this grant application is to develop next generation single guide RNAsgRNAwhich is a critical component for CRISPR Casknockout assaysThe sgRNA determines both the efficacy and specificity of CRISPR Casediting activitie ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Smart Sensor Bandage for Ulcer Monitoring

    SBC: STOECKER MD, WILLIAM V            Topic: 600

    AbstractSmart Sensor Bandage for Ulcer Monitoring Non healing pressure ulcers result in approximately $billion in additional treatments each year in the United Statesraising in hospital mortality by nearly threefold and lengthening hospital stay by more than double when ulcers are presentThis burden is particularly pronounced in assisted living facilities where occurrence is high and skilled nursi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Glycoengineering a bioconjugate vaccine against Klebsiella pneumoniae

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Klebsiella pneumoniae is an increasingly prevalent drug resistant nosocomial pathogenCommonlyKpneumoniae isolates are carbapenem resistantwhich are referred to as carbapenem resistant EnterobacteriaceaeCREand present significantly less therapeutic intervention optionsFurthermorecommunity acquired infections associated with hypervirulent isolates of Kpneumoniae have emerged that are ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government